Literature DB >> 16341096

Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.

Bryan T Hennessy1, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16341096     DOI： 10.1038/ncponc0375

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


× No keyword cloud information.
  3 in total

1.  Small breast epithelial mucin (SBEM) has the potential to be a marker for predicting hematogenous micrometastasis and response to neoadjuvant chemotherapy in breast cancer.

Authors:  Zhao-Zhe Liu; Xiao-Dong Xie; Shu-Xian Qu; Zhen-Dong Zheng; Ya-Kun Wang
Journal:  Clin Exp Metastasis       Date:  2010-04-03       Impact factor: 5.150

2.  HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.

Authors:  Daniel G Tiezzi; Jurandyr M Andrade; Alfredo Ribeiro-Silva; Fábio E Zola; Heitor R C Marana; Marcelo G Tiezzi
Journal:  BMC Cancer       Date:  2007-02-26       Impact factor: 4.430

3.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Authors:  Marc Tischkowitz; Jean-Sébastien Brunet; Louis R Bégin; David G Huntsman; Maggie C U Cheang; Lars A Akslen; Torsten O Nielsen; William D Foulkes
Journal:  BMC Cancer       Date:  2007-07-24       Impact factor: 4.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.